Skip to main content
. 2021 Jun 10;16(7):1662–1673. doi: 10.1016/j.stemcr.2021.05.003

Table 1.

The advantages of MSC-derived exosomes over their parent cells

MSC MSC-derived exosomes
Risk of tumorigenicity low no
Immune rejection low no
Stability low high
Production cost high low
Therapeutic efficacy after systemic delivery low high

MSC, mesenchymal stromal cell.